HANDBOOK of Pharmaceutical

Generic Development



VOLUME 10 - Part ONE

DRUG Development - Solid CR Oral Dosage Forms

DRUG DEVELOPMENT

The Complete Handbook Series of Pharmaceutical Drug Development

ISBN 0793 8632 - Electronic Version - Handbook Development 24 Volume Series ISSN Series Number 0793 761X - Electronic Version

Handbook of Pharmaceutical Generic Development Part I (Drug Development) & Part II (Development/Formula & ANDA) Handbook of Pharmaceutical Generic Development Part I (Drug Development) & Part II (Development/Formula & ANDA) Handbook of Pharmaceutical Generic Development Part I (Drug Development) & Part II (Development/Formula & ANDA) Handbook of Pharmaceutical Generic Development Part I (Drug Development) & Part II (Development/Formula & ANDA) Handbook of Pharmaceutical Generic Development Part I (Drug Development) & Part II (Development/Formula & ANDA) Handbook of Pharmaceutical Generic Development

Handbook of Pharmaceutical Generic Development Part I (Development) & Part II (Development ANDA or EU Dossier) Handbook of Pharmaceutical Generic Development Part I (Drug Development) & Part II (Development/Formula & ANDA) Handbook of Pharmaceutical Generic Development Part I (Drug Development) & Part II (Development/Formula & ANDA) Handbook of Pharmaceutical Generic Development Part I (Drug Development) & Part II (Development/Formula & ANDA) Handbook of Pharmaceutical Generic Development Part I (Drug Development) & Part II (Development/Formula & ANDA) Handbook of Pharmaceutical Generic Development Part I (Drug Development) & Part II (Development/Formula & ANDA) Handbook of Pharmaceutical Generic Development Part I (Method Validation) & Part II (Analytical Methods 1994-2003)

Handbook of Pharmaceutical Innovative Development Handbook of Pharmaceutical Innovative Development

Handbook of Pharmaceutical Innovative Development

Handbook of Pharmaceutical Drug Development (Master Formula & Manufacturing Instructions Parts 1 - 5)

Handbook of Pharmaceutical Drug Development (Master Formula & Manufacturing Instructions Parts 6 -10)

Handbook of Pharmaceutical Innovative Development Part I, II & III (Development, Manufacturing & Engineering)

Handbook of Pharmaceutical Drug Development Part I (Drug Development) & Part II (Development/Formula & ANDA)

Handbook of Pharmaceutical Generic Development Vol. 21 - Chew Tablets Part I (Drug Development) & Part II (Development/Formula & ANDA)

Vol. 1 - Tablets Oral

Vol. 2 - Capsules Oral

Vol. 3 - Semisolids

Vol. 4 - Liquids Oral

Vol. 5 - SG Capsules

Vol. 6 - e-SOPs / SOPs

Vol. 7 - Suspensions

Vol. 8 Sterile Eye Preps

Vol. 9 - Nasal Preparations

Vol. 10 -Tablets CR/MR

Vol. 11 - Capsules ER

Vol. 12 - Tablets Oral DR

Vol. 13 - Analytical (Top 50 Generic Assay Methods)

Vol. 14 - Tablets Oral

Vol. 15 - Capsules Oral

Vol.16 Suspensions Oral

Vol. 17 - MF and MMI

Vol. 18 - MF and MMI

Vol. 19-SOPs/PAI-Checklist

Vol. 20 - Sterile Injections

Add-on modules of Pentoxifylline ER; Gabapentin ER, Glipizide ER; Felodipine ER; Naproxen DR, Sinemet ER. Available as print soft bound or Spiral Cover for updating.and on CD ROM Additional Drug Specific Volumes in Preparation

For Drug Specific Handbooks refer to the 120+ Drug Development Series titled READY-TO-GO™ DRUG DEVELOPMENT SERIES

□ http://www.locumusa.com/2go - An on-going electronic and print series - http://www.iagim.org □



Handbook of Pharmaceutical Generic Development

Oral

PART ONE
DRUG DEVELOPMENT

CR Tablets



Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming and recording, or by any information storage and retrieval system, without the permission of the publishers.

Copyright © Locum Publishing House Inc. All Rights Reserved.

A Locum House Publication

HPGD Series CR Tablets Oral - Part I

First & Second Int. Edition - 01 & 02 (First & second print run) Published 1995/6/7/8. **T**hird International Edition - 03 (1st, 2nd and 3rd printing) - Published 1999/2000/2001.

Forth and Fifth International Edition - 04 / 05 (First & second print) - Jan / July 2002/2003/2004 Sixth International Edition - 06 (2^{nd} Print) - Publishing November Effective May 2005 Published and distributed in UK, US, EU, Israel, Asia, and Japan in by Locum International Publishing House (Houston, Israel, South Africa) in Hard Cover; Soft and Spiral Cover; Electronic CD ROM; and Online Editions. All print and electronic editions are identical in content and format.

Seventh International Edition - 07 (1st Print) - Publishing November Effective April 2006

Eight International Edition - 08 (1st Print) - Publishing November Effective January 2007

Ninth International Edition - 09 (1st Print) - Publishing November Effective January 2008

Tenth International Edition - 10 (1st Print) - Publishing November Effective April 2009

Eleventh International Edition - 11 (1st Print) - Publishing November Effective April 2010

Copyright © 1995 Handbook of Pharmaceutical Generic Development.

Text Copyright © 1995 Handbook of Pharmaceutical Generic Development. Illustration copyright © 1995 Handbook of Pharmaceutical Generic Development. Locum International Group Publishing House 562 Monaco L Monaco Blvd. Delray Beach Florida 33446-1938 USA - All right reserved.

ISBN 0793 8705 - Electronic Version (CD ROM and On-line editions)

ISBN 0793 8691 - Handbook Development 24 volume series

General Generic Development ISSN Series number 0793 7407

General Generic Development ISSN Series number 0793 7792 - Electronic Issue (CD ROM and Online are identical in size and content to the printed soft cover version.)

Duplication: No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without the prior written permission of the copyright owner or subject to the following conditions:

Authorization to photocopy items for internal or personal use or internal or personal use of specific company personnel is granted by Locum International Publishing House, provided that the base fee of \$1 per page is paid directly to the Copyright Clearance Center (CCC) 222 Rosewood Drive, Danvers, MA 01923 USA.

For organizations that have been granted a photocopy license by CCC, a separate system of payment has been arranged. US printing Locum USA Publishers, Block J, 562 Monaco L Delray Beach 33446-1938 Florida USA.

For additional information, contact the Group Publications Department Locum International Publishing House; PO Box 874, 50 Gilad Street, Kochav Yair, 44864 Israel.



Current Printing (last digit): 10 9 8 7 6 5

US Fax: +1-561-431 2620
Global Orders Fax: +972-3-725 5751
E-mail: info@locumUSA.com
 http://www.locum.co.il
http://www.locumeuro.com
 http://www.locumusa.com
 info@locumUSA.com
 info@locumGroup.org

PRINTED IN USA
PRINTED IN ISRAEL
PRINTED IN IRELAND
PRINTED IN REPUBLIC OF SOUTH AFRICA

SERIAL NUMBER - DO NO REMOVE! - REGISTERED WITH

ACKNOWLEDGMENTS

I.A.G.I.M. (R&D) Foundation
I.A.G.I.M. Research Council
Contributions - Generic & Research Firms
Associate Universities, Technicons & Consultants.
Handbook Series Coordinating Committee,
International Journal of Drug Development.
International Journal of Drug Formulation.
Journal of Pharmaceutical Development.
International Journal of Generic Drugs.
International Journal of Drug R&D
I.A.G.I.M. Drug Development Archives
Locum International Archives.
FDA/OGD/CDER Maryland
Guides and Guidelines
Library of Congress.
AIC Conferences.
Editorial Board.
Pharm. Eur.
USP/NF.
USP/NF.
USPC.
BP.

To Doribelle
for her years of support and help
to Sean for his expert knowledge on computerization
to David and Ari for running the project's computers
and lastly to Pat for his inestimable
contribution.

Locum International Press
24 Volume Drug Development Series
Handbook of Pharmaceutical Generic Development
International Edition.



EDITORIAL PREFACE

Handbook of Generic Drug Development - ORAL CR TABLETS

This handbook represents the **current** International Edition of the ongoing **24** volume *series* of Generic Drug Development and appears under the cumulative title of the Handbook *series* of Generic Drug Development. The full reference series is updated annually at the end of each year. This is an ongoing process as new data, specifications and process techniques are added on a continual and expanding basis. This handbook is fact never fully complete as each new annual edition brings an enlarged and extended profile in the drug development process, as well as new agency rules, guidelines and guidance to industry which continues to be added year by year as the global product data base expands. Currently over 350 scientific publications and tens of drug development conferences are annually referenced in the **24** volume Handbook *series* of Generic Drug Development.

This mammoth task presents a continual ongoing commitment by the scientific review committee to the improvement of the technical databases and the product specific drug development requirements and know-how technology accessed through the world wide IAGIM joint ventures and know-how projects currently active in over 15 countries.

The Handbook is available in electronic format (CD ROM) and the **e-**format is up-dated annually to association members of IAGIM – Drug Development Association.

This revised international edition of the Handbook has been redesigned and updated to meet the **current** Guidance for Industry - Organization of an Abbreviated New Drug Application and an Abbreviated Antibiotic Application as well as all current approved and *draft* FDA guideline requirements of the Center of Drug Evaluation and Research (CDER) up to date of publishing



ISSN 0793 8656 n on-going series

Six Add-on Modules to this HandBook Purchased Separately Consists of:

Pentoxifylline ER; Gabapentin ER; Glipizide ER;

Felodipine ER; Naproxen DR; Sinemet ER.

Additional Volumes in Preparation
General Drug Development Series ISSN 0973 7601
Electronic Drug Development Series ISSN 0973 761X



Contents


PHARMACEUTICAL DEVELOPMENT

Table of Contents	VI
Acronyms - Abbreviations	XIII
Introduction	XV
Preface	XVI
Forward	XVII
Chapter 1	
Regulatory	1.1
- Pre-formulation checklist	1.3
Documentation	1.4
- Getting the Right Documentation	1.5
Development Notebooks	1.8
- Development Notebooks checklist	1.10
- SOP Control and Development Notebooks SOPs	1.11
Chapter 2	
D 1 1 4 5 1 4 0 5 0 1	
Developing the Formula -A CR Overview	2.1
- Development Flowchart	2.1 2.4
- Development Flowchart	2.4
- Development Flowchart Development CR Formula Checklist	2.4 2.5
- Development Flowchart Development CR Formula Checklist Development Formula CR	2.42.52.6
- Development Flowchart Development CR Formula Checklist Development Formula CR Using a typical IVIV Model - typical IVIVC Models Choosing IVIVC levels	2.42.52.62.7
- Development Flowchart Development CR Formula Checklist Development Formula CR Using a typical IVIV Model - typical IVIVC Models Choosing IVIVC levels CR Formula development Checklist	2.4 2.5 2.6 2.7 2.8 2.9
- Development Flowchart Development CR Formula Checklist Development Formula CR Using a typical IVIV Model - typical IVIVC Models Choosing IVIVC levels CR Formula development Checklist Product Development SOPs List	2.4 2.5 2.6 2.7 2.8 2.9 2.11
- Development Flowchart Development CR Formula Checklist Development Formula CR Using a typical IVIV Model - typical IVIVC Models Choosing IVIVC levels CR Formula development Checklist Product Development SOPs List Developing the Formula	2.4 2.5 2.6 2.7 2.8 2.9 2.11 2.13
- Development Flowchart Development CR Formula Checklist Development Formula CR Using a typical IVIV Model - typical IVIVC Models Choosing IVIVC levels CR Formula development Checklist Product Development SOPs List Developing the Formula Product Development Flow Chart	2.4 2.5 2.6 2.7 2.8 2.9 2.11 2.13 2.19
- Development Flowchart Development CR Formula Checklist Development Formula CR Using a typical IVIV Model - typical IVIVC Models Choosing IVIVC levels CR Formula development Checklist Product Development SOPs List Developing the Formula Product Development Flow Chart Product Development Tabulated Chart (24 Stages)	2.4 2.5 2.6 2.7 2.8 2.9 2.11 2.13 2.19 2.21
- Development Flowchart Development CR Formula Checklist Development Formula CR Using a typical IVIV Model - typical IVIVC Models Choosing IVIVC levels CR Formula development Checklist Product Development SOPs List Developing the Formula Product Development Flow Chart Product Development Tabulated Chart (24 Stages) CR Formula development SOP Checklist	2.4 2.5 2.6 2.7 2.8 2.9 2.11 2.13 2.19 2.21 2.29
- Development CR Formula Checklist Development Formula CR Using a typical IVIV Model - typical IVIVC Models Choosing IVIVC levels CR Formula development Checklist Product Development SOPs List Developing the Formula Product Development Flow Chart Product Development Tabulated Chart (24 Stages) CR Formula development SOP Checklist Purified Water - An essential ingredient	2.4 2.5 2.6 2.7 2.8 2.9 2.11 2.13 2.19 2.21 2.29 2.31
Development CR Formula Checklist Development Formula CR Using a typical IVIV Model - typical IVIVC Models Choosing IVIVC levels CR Formula development Checklist Product Development SOPs List Developing the Formula Product Development Flow Chart Product Development Tabulated Chart (24 Stages) CR Formula development SOP Checklist Purified Water - An essential ingredient Do and Don'ts in Development	2.4 2.5 2.6 2.7 2.8 2.9 2.11 2.13 2.19 2.21 2.29 2.31 2.34
- Development CR Formula Checklist Development Formula CR Using a typical IVIV Model - typical IVIVC Models Choosing IVIVC levels CR Formula development Checklist Product Development SOPs List Developing the Formula Product Development Flow Chart Product Development Tabulated Chart (24 Stages) CR Formula development SOP Checklist Purified Water - An essential ingredient	2.4 2.5 2.6 2.7 2.8 2.9 2.11 2.13 2.19 2.21 2.29 2.31

Contents



Chapter	3	
Active Ingredients -Do's and Don'ts		3.1 3.2
-Active Checklist		3.3
-Approved Suppliers Checklist	20	3.5 3.6
 -Standard Operating Procedures, Active -Alternative Pharmaceutical Sources 	25	3.7
Chapter	4	
Semi active ingredients		4.1
-Validating the Semi-active ingredients,	Checklist	4.3
Non Active Excipients		4.4 4.8
Non Active general scheme Non Active release controlling excipient	ts	4.0 4.10
Non Active excipients checklist		4.11
Qualifying the Antioxidant		4.13
Antioxidant Tabulations		4.14
Chapter	5	
Container closure systems	A SE MAN	5.1
-Container-liner-closure systems, Check-Container-liner-closure systems, SOPs		5.2 5.4
-Packaging Components		5.5
 Packaging Components Documentation Packaging Components Test Requirem 		5.6 5.16
	_	5.10
Chapter	6	
Manufacturing Instructions - Manufacturing Instructions; Checklist		6.1 6.4
- The manufacturing Instructions and Co	ontrols	6.5
- Master Formula		6.6
- Manufacturing Flow Charts	_	6.18
Chapter	7	
In-process Quality Controls -Manufacturing in-process controls; Che	acklist	7.1 7.2
-In-process Quality Controls - overview	SONIST	7.5
-In-process Quality Controls - productio		7.6
 -In-process Quality Controls - quality co -In-process Quality Controls - specificat 		7.7 7.8
-In-process Quality Controls - specificat	ion - cores	7.9
-In-process Quality Controls - specificat	ion - coated	7.10



Contents

Chapter 8	
Finished Product Specifications	8.1
- Finished Product Specifications Release Checklist	8.2
- Finished Product Specifications Stability Checklist	8.3
- Finished Product Specifications; Required SOPs	8.6
Chapter 9	
Process Optimization and Procedures	9.1
Qualification of Antioxidant and Lubricant	9.3
Optimization Limits	9.5
Process Optimization flow Chart	9.7
Chapter 10	
Scale-up Procedures	10.1
- Scale-up procedures; checklist	10.5
- Scale-up procedures; SOPs	10.6
Chapter 11	
Cleaning Limits	11.1
Cleaning Limits Procedures; Checklist	11.6
Cleaning Validation Requirements; SOPs	11.8
Cleaning Procedures; As the FDA see it.	11.9
Chapter 12	
Analytical Validation Requirements	12.1
-Analytical Testing Out of Specification -Analytical Testing Do's and Don'ts	12.21 12.23
Analytical Testing Out of Specification	12.27
-Ruggedness and Robustness	12.37
-Impurities in Drug Substances	12.41
-Impurities Do's and Don'ts	12.50
-Impurities Glossary of terms	12.52
-Impurities Decision Trees Analytical Post approval Changes -PAC-ALTS	12.53 12.55
PAC-ALTS Checklist	12.58
Chapter 13	
Process Qualification Batch	13.1
-Process Qualification Batch; Checklist	13.2
-Process Qualification Batch; SOPs	13.3
-Process Qualification Blend Analysis	13.5
-Process Qualification Blend Analysis - Do's and Don'ts -Process Qualification - Qualifying Tablet Hardness	13.7 13.9
Tablet Hardness Protocol	13.10
1 42.01 1 14.01000 1 10.0001	10.10

JUP'S

Table of Contents

Contents

Chapter	14	
Pivotal batch		
-The Pivotal Batch		14.1
-Pivotal batch Checklist		14.2
-Pivotal batch SOPs-Sampling and Testing the Pivotal B	eatch .	14.3 14.5
-Auditing the Pivotal batch	odicii	14.10
-Auditing the Pivotal batch Checklis	t	14.11
Chapter	15	
Chapter PA & RE Overview	2 13	15 1
BA & BE Overview B ioequivalence vs. Reference Liste	d Drug	15.1 15.27
Statistical Bioequivalence	a Drug	15.27
Test Designs - Overview		15.38
IBE Equation explained		15.40
IBE Big Picture (Pros and Cons)		15.41
Comparing IBE and ABE	and the same of th	15.42
Dissolution Testing in MR Dosage F	Forms	15.43
Model Two and three way studies BA-BE Food-Effects in BA-BE Studi	inc.	15.44 15.48
Food-Effects in BA-BE Studies	65	15.50
Side-by-side comparison		15.55
Bioanalytical Methods		15.56
Biopharmaceutics Classification Sys	stem	15.72
Generic Drug Dissolution and RLD		15.88
Performance Verification in Dissolut		15.95 15.123
Similarity Testing - Chow, Pitt and C Similarity Factor in dissolution testing		15.123 15.127
		10.127
Chapter	16	
T echnical Transfer Documentation		16.1
-Technical Transfer Documentation		16.2
 -Technical Transfer Documentation -Technical Transfer Documentation 		16.5 16.7
-Technical Transfer Documentation		16.7
	47	
Chapter	17	
Process Validation batches	a addicat	17.1
-The Process Validation Batches; cl		17.2 17.4
-Process Validation Requirements;-Process Validation Master Plan	SOF 9	17. 4 17.5
-Prospective Validation Protocol		17.8

20.11

20.19

20.23

Generic Development



Contents

Chapter	18	
PreApproval Inspections		18.1
PAI Summary		18.8
PreApproval Inspection Audit -		18.9
PreApproval Inspection Audit -	Team Activities	18.10
Chapter	19	
Stability Testing of Drug Substa	nce and Drug Product I	19.1
Stability Testing of Drug Substa	ince and Drug Product II	19.15
Stability Testing of Drug Substa	ince and Drug Product III	19.21
Stability Testing Significant Cha	ange	19.24
Stability Testing Significant SO	P De la company	19.25
Storage Conditions		19.29
Setting up a functional Stability	Unit	19.31
Photostability in New Drug Prod	ucts	19.39
Photostability Flowchart		19.47
Stability SOPs Development		19.49
Chapter	20	
Standard Operational Prod	edures	
Development SOPs		20.1
Index of Pharmaceutical Standar	d Operating Procedures	20.3



An on-going Handbook Series Additional Volumes in Preparation

ISSN 0793 8640 - Electronic Version Handbook Development 24 Volume *Series* ISSN Series Number 0793 7792 - Electronic Version.

Index of Analytical Standard Operating Procedures

Index of Stability Standard Operating Procedures

Index of Microbiological Standard Operating Procedures

ORAL CR TABLETS Table of Contents

EDITORIAL PREFACE

Handbook of Generic Development - Oral Tablet Dosage Form

This expanded International Edition of the Handbook 24 volume *series* of the ongoing of Generic Drug Development and appears under the cumulative title of the Handbook *Series* of Generic Drug Development. The ongoing series is updated annually at the end of each year. This is an ongoing process as new data, specifications and process techniques are added on a continual and expanding basis. This handbook is continually updated and revised, as each new annual edition brings an enlarged and extended profile in the drug development process, as well as new agency rules, guidelines and guidance to industry which continue to be added year by year as the global product data base expands.

Currently over 150 scientific publications and drug development conferences are annually referenced in the 24 volume Handbook series of Generic Drug Development.

This mammoth task presents a continual ongoing commitment by the scientific review committee to the improvement of the technical databases and the product specific drug development requirements and know-how technology accessed through the world wide IAGIM joint ventures and know-how projects currently active in over 15 countries.

The Handbook is available in electronic format (CD ROM) and the e-format is up-dated annually to association members of IAGIM.

This international edition of the Handbook is redesigned to meet the latest - Guidance for Industry - Organization of an Abbreviated New Drug Application as well as all key draft and final FDA guidelines and requirements of the Center of Drug Evaluation and Research (CDER - OGD 1)

- Editor-in-Chief.



Additional Volumes in Preparation
General Drug Development Series ISSN 0973 7601
Electronic Drug Development Series ISSN 0973 761X

ÓŠ Î
International Print Edition
pLocum±Pressp
© COPYRIGHT
Ï > Đ

Generic Development